Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company based in Foster City, California, focused on developing therapies for rare liver diseases. Founded in 2018, Mirum aims to transform the treatment landscape for these conditions by creating safe and effective medicines. The company's name reflects its mission to deliver remarkable therapies for individuals living with rare diseases. Mirum has three approved medicines: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets. LIVMARLI® is specifically approved for treating cholestatic pruritus in patients with Alagille syndrome and primary familial intrahepatic cholestasis. Cholbam® addresses bile acid synthesis disorders, while Chenodal® is used for the dissolution of cholesterol gallstones. The company is dedicated to supporting patients and families affected by rare liver diseases, emphasizing community engagement and awareness. Recently, Mirum expanded its capabilities by acquiring assets from Travere Therapeutics, further enhancing its commitment to addressing the needs of those with rare diseases.